Alameda Advisors Inc.

Converting Innovation to Sustainable Business
Our team consists of seasoned professionals with decades of experience as business executives,
serial entrepreneurs, investors and turnaround leaders.  Our team has been covered in the press
and news, spoken at conferences and has many publications.  Our expertise covers business,
marketing, finance and many leading technologies.  All team members have advanced degrees plus
long track records of achievements.
Our Team
Associates and
Dr. Philip Barr
Philip J. Barr, Ph.D., is currently assisting the redirection of Arriva
Pharmaceuticals, Inc., an Alameda, California-based biotechnology
company.   Phil has served as Chief Science officer as well as President
and Chief Operating Officer and a Director of Arriva Pharmaceuticals. Dr.
Barr has also been an Adjunct Professor of Pharmaceutical Chemistry at
the University of California, San Francisco since 1985. Arriva focuses on
biopharmaceuticals via pulmonary administration for the treatment of
emphysema, asthma and cystic fibrosis. Other current scientific and
commercial interests of Dr. Barr include: production and manufacture of
recombinant proteins in yeast; the treatment of respiratory diseases using
protease inhibitors; and recombinant proteins for oncology applications.

From his experience and involvement in commercial biotechnology since
the early 1980s, Dr. Barr has a unique and valuable perspective on
current platform technologies within the biotechnology field, and is highly
proficient in evaluating emerging technologies in the biomedical area.
Having been the former Director of Molecular Biology of Chiron
Corporation, he has particular expertise in the production of
biopharmaceutical products for the treatment and diagnosis of human

Dr. Barr is a citizen of the U.K., and has permanent residence status in the
US. He holds a B.Sc. (Hons) and Ph.D. in Chemistry, University of
Birmingham, U.K. (1975, 1978), and won a Post-Doctoral Scholarship in
Chemistry, University of Alberta, Canada, a Post-Doctoral Fellowship in
Pharmaceutical Chemistry, University of California, San Francisco. He
has published over 180 peer-reviewed articles in the scientific literature,
and is named as an inventor on 27 issued U.S. patents.